Drug
recombinant human chorionic gonadotropin
recombinant human chorionic gonadotropin is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_3
2
50%
Ph not_applicable
2
50%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 3
Trials by Phase
Phase 32 (50.0%)
N/A2 (50.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
terminatednot_applicable
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations
NCT00700778
completedphase_3
A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation
NCT02449889
completedphase_3
Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
NCT00747617
completednot_applicable
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
NCT00989781
Clinical Trials (4)
Showing 4 of 4 trials
NCT00700778Not Applicable
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations
NCT02449889Phase 3
A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation
NCT00747617Phase 3
Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
NCT00989781Not Applicable
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4